Global Angelman Syndrome Treatment Market – Industry Trends and Forecast to 2030

Angelman Syndrome Treatments Market Analysis and Size

The incidence of angelman syndromes can vary among different populations and age groups. However, the increase in government initiatives in developing treatment options for angelman syndrome drives the global angelman syndrome treatment market. Moreover, increased health and R&D expenditure also boosts the market growth.  

Data Bridge Market Research analyses that the angelman syndrome treatment market which was USD 143.77 million in 2022, would rocket up to USD 220.64 million by 2030, and is expected to undergo a CAGR of 5.5% during the forecast period. This indicates the market value. “physical therapy” dominates the treatment segment of the angelman syndrome treatment market owing to the growing demand for better surgical methods for treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Angelman Syndrome Treatments Market Scope and Segmentation

Market Definition

Angelman syndrome is a very rare genetic disorder that affects the nervous system. This syndrome is caused by a loss of function in the UBE3A gene on the maternal 15th chromosome. People suffering from angelman disorder have excitable personalities and they frequently laugh and smile. Major symptoms of angelman syndrome are lack of speech, balance issues and seizures. Sometimes tongue thrusting, Jerky movement may occur.

Global Angelman Syndrome Treatments Market Dynamics

Drivers

• Rising prevalence of speech disorders

The rising prevalence of speech disorders such as stuttering, apraxia, and others among children and adults is expected to fuel the global angelman syndrome treatments market. Furthermore, the rising prevalence of chronic illnesses such as brain injuries, tumours, Parkinson's disease, autism, cerebral palsy and stroke is also expected to drive the global angelman syndrome treatments market. Expressive disorders, voice disorders, articulation disorders, fluency disorders, and language disorders such as receptive disorders and cognitive-communication disorders are all instances of speech disorders. The emergence of these disorders is boosting the global angelman syndrome treatments market.

• Increasing investment in healthcare infrastructure

Another significant factor influencing the growth rate of angelman syndrome treatments market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Opportunities

• Research and development proficiencies

Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the angelman syndrome treatments and will further create lucrative market growth opportunities. Research and development proficiencies being conducted to provide best of the medications to curb the Angelman Syndrome is also bolstering the market growth rate.

• Increase in the number of research and development activities       

The increase in the number of research and development activities is estimated to provide various beneficial opportunities for the neurological disorder drugs market’s growth. New therapeutic techniques for the treatment of angelman syndrome are being adopted by companies in the neurological disorder pharmaceuticals market. This leads to high number of research activities to better understand the disease's genetic risk factors in order to find better drugs.

Restraints/Challenges

• Hight costs associated with the research and development activities

The high cost associated with the research and development activities will obstruct the growth rate of market

This angelman syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Angelman Syndrome Treatment market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Development

• In September 2021, Sumitomo Dainippon Pharma and Otsuka announced a collaboration as well as license agreement for four psychiatry and neurology compounds namely ulotaront (SEP-363856), SEP-4199, SEP-378614, and SEP-380135. Under the terms of the partnership, Sunovion and Otsuka will split the costs and revenues of clinical trials, regulatory applications, and commercialization in each of these nations and areas. Additional ulotaront indications, and also SEP-378614 and SEP-380135 indications, will be identified after future Sumitomo Dainippon Pharma Group and Otsuka consultations.

Global Angelman Syndrome Treatment Market Scope

The angelman syndrome treatment market is segmented on the basis of treatment, service provider, diagnostic test and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Physical Therapy
• Communication Therapy
• Behavior Therapy
• Others

 Service Provider

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Diagnostic Test

• DNA methylation test
• Chromosomal Microarray (CMA)
• Gene mutation Tests
• Other

End Users

• Clinic
• Hospital
• Others

Global Angelman Syndrome Treatment Market Regional Analysis/Insights

The global angelman syndrome treatment market is analysed and market size insights and trends are provided by country, treatment, service provider, diagnostic test and end-users as referenced above.

The countries covered in the angelman syndrome treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the angelman syndrome treatment market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having Angelman Syndromes such as moles, warts and skin tags.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for skin care, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The angelman syndrome treatment market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the Angelman Syndrome treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the Angelman Syndrome market.

Competitive Landscape and Angelman Syndrome Treatment  Market Share Analysis

The angelman syndrome treatment market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the angelman syndrome treatment market.

Some of the major players operating in the angelman syndrome treatment market are:

• Smart Speech Therapy (U.S.)

• SPEECH THERAPY SOLUTIONS, INC. (U.S.)

• Talk Speech and Language Therapy Ltd. (U.K.)

• Glenda Browne Speech Pathology (Australia)

• Benchmark Therapies, Inc (U.S.)

• speech plus (U.S.)

• Integrated Treatment Services (U.S.)

• Speechworks Therapy Services (U.S.)

• Acapela Group (Belgium)

• Advanced Voice Recognition Systems, Inc. (U.S.)

• Open Text Corporation (Canada)

• Cleveland Clinic (U.S.)

• Therapy Solutions Inc (U.S.)

• Merck KGaA (Germany)

• Eisai Co., Ltd. (Japan)

• AstraZeneca (U.K.)

• Sanofi (France)

• Novartis AG (Switzerland)

• Abbott (U.S.)

• F. Hoffmann-La Roche Ltd. (Switzerland)

• Teva Pharmaceutical Industries Ltd. (Ireland)

• Pfizer Inc. (U.S.)

• GlaxoSmithKline plc (U.K.)

SKU-60302